Stellenangebot: Postdoctoral Researcher – CAR T-Cell Development and Tumor Immunology (m/w/d) bei Klinikum der Universität München

Das Wichtigste im Überblick

Besondere Merkmale

  • Beginn ab 01.01.2027

Arbeitsort

München

Angebotsart

Arbeit

Anstellungsart

Vollzeit

Berufsbezeichnung

  • Biologielaborant/in

Stellenbeschreibung

Scope of duties

· Develop and optimize CAR constructs and support their transfer into a scalable retroviral vector system
· Generate and characterize CAR T cells and assess their functionality in vitro using AML cell lines and primary patient samples
· Investigate CAR T-cell cytotoxicity, activation, differentiation, and proliferation.
· Evaluate potential off-target effects and hematopoietic toxicity using humanized mouse models and healthy human tissue explant models
· Analyze experimental data, document results, and contribute to scientific publications and preclinical safety evaluation
· Collaborate with interdisciplinary research teams within the CARAMeL consortium

Our requirements

· PhD, MD, PharmD, DVM, or an equivalent doctoral degree in immunology, molecular or cell biology, biochemistry, biomedical sciences, or a related field

· Strong experimental research experience and a good publication record
· Solid knowledge of immunology and cell biology, with practical experience in cell culture and functional assays
· Experience in one or more of the following areas is highly desirable: CAR T-cell engineering, viral vector technology, flow cytometry, or preclinical in vivo models
· Strong analytical skills and an independent, structured approach to research
· High motivation, initiative, and the ability to work collaboratively in an international research environment
· Excellent written and spoken English

Our offer

· Contract duration: 2 years fixed-term
· The Institute of Clinical Pharmacology at LMU University Hospital Munich offers an interdisciplinary research environment at the interface of experimental immunology, innovative cell therapies, and translational medicine

· The research group of Prof. Dr. Sebastian Kobold focuses on developing novel cancer immunotherapies, particularly cellular therapies and antibody-based approaches
· This position is part of the CARAMeL consortium, funded by the German Cancer Consortium (DKTK). The project aims to advance an innovative CAR T-cell therapy for patients with relapsed or refractory acute myeloid leukemia (AML). A key objective is to improve therapeutic efficacy while minimizing damage to healthy hematopoietic stem and progenitor cells
· The successful candidate will contribute to translating the CAR technology into a scalable retroviral vector system and investigating the functionality and preclinical safety of the resulting CAR T cells. The work will be conducted in close collaboration with national and international research partners

Arbeitsorte

Unternehmensdarstellung: Klinikum der Universität München

Informationen zur Bewerbung